PKM and myeloid sarcoma: Finally, we found that PBMCs from patients with MS have a higher percentage of PKM2 monomer compared to PBMCs from HCs, supporting heightened PKM2 moonlighting activity.<h4>Interpretation</h4>Our data suggest that PKM2 may represent a therapeutic target to limit T cell-driven inflammation in MS and potentially other human autoimmune diseases.<h4>Funding</h4>Austrian Multiple Sclerosis Research Society, Kulturamt der Stadt Graz, MEFOGraz and Worldwide Cancer Research.